Pietro Scaparone
YOU?
Author Swipe
View article: Novel <scp>RAF</scp>‐directed approaches to overcome current clinical limits and block the <scp>RAS</scp>/<scp>RAF</scp> node
Novel <span>RAF</span>‐directed approaches to overcome current clinical limits and block the <span>RAS</span>/<span>RAF</span> node Open
Mutations in the RAS–RAF–MEK–ERK pathway are frequent alterations in cancer and RASopathies, and while RAS oncogene activation alone affects 19% of all patients and accounts for approximately 3.4 million new cases every year, less frequent…
View article: Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer Open
View article: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer Open
View article: How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer Open
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is th…